---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-072689"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2024-03-20T23:59:59+00:00"
generated_at: "2026-06-04T11:45:21.549386+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Homology Medicines approves 1-for-18 reverse stock split effective March 25 in connection with Q32 merger

## Summary
- Board approved reverse stock split at 1-for-18 ratio; every 18 shares combine into one.
- Reverse split effective at market open on March 25, 2024; Certificate of Amendment filed March 22.
- No fractional shares issued; stockholders receive cash in lieu based on March 22 closing price.
- Reverse split is a condition to closing of the merger with Q32 Bio Inc.
- Post-split common stock trades under new CUSIP 746964105.

## SEC filing metadata
- accession: 0001193125-24-072689
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2024-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312524072689/0001193125-24-072689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312524072689/d808597d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-072689
- JSON: https://secwatch.observer/filing/0001193125-24-072689.json
- Plain text: https://secwatch.observer/filing/0001193125-24-072689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.